Kang 2 on kidney in rats with nephrotic syndrome during hormone therapy Withdrawal_0.docVIP

 PAGE \* MERGEFORMAT 12 Kang 2 on kidney in rats with nephrotic syndrome during hormone therapy Withdrawal [Abstract] Objective To investigate the kidney and spleen, kidney health medicine 2, hormone therapy in the nephrotic syndrome in rats by the time of withdrawal of the hypothalamus - pituitary - adrenal axis (HPA axis) the impact of its withdrawal by hormones in the nephrotic syndrome, maintenance treatment phase of the theoretical basis for clinical application. Methods Adriamycin rat model of nephrotic syndrome, to the high-dose glucocorticoid therapy cause HPA axis suppression, the hormone reduced gradually withdrawn, while for 2 different doses of irrigation Shenkang stomach, kidney Kang observed after 2 weeks, 2 large, low-dose group and control group, hormone, nephrotic syndrome model group, normal group serum adrenocorticotropic hormone (ACTH), cortisol levels and adrenal morphological changes. results in hormone After Withdrawal, Shen Kang 2, large and small dose group and control group, blood hormone ACTH, cortisol levels were gradually increased, although after 2 weeks were not restored to normal levels, but the large and small dose group, blood ACTH, cortisol levels were higher than the hormone group (P lt;0.05), while the high dose group was higher than the low dose group (P lt;0.05); large and small doses of adrenal cortical atrophy and the cells with a fascicular arrangement of light on the hormonal disorder case control group, The high dose group was lighter than low-dose group. Conclusion of renal medicine has improved health 2, glucocorticoid induced inhibition of HPA axis function, suggesting that we may be extended when the clinical course of drugs and dosage. [Keywords:] Shen Kang 2; the hypothalamus - pituitary - adrenal axis; adrenocorticotropic hormone; cortisol; rat Abstract: Objective To observe the effect of Shenkang-Ⅱ on hypothalamus-pituitary-adrenal axis (HPA axis) in nephrotic syndrome rats during high-dose glucocorti